A share price of Kiniksa Pharmaceuticals International Plc [KNSA] is currently trading at $29.11, up 4.26%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KNSA shares have gain 9.89% over the last week, with a monthly amount glided 5.28%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] stock has seen the most recent analyst activity on March 13, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $40. Previously, Jefferies started tracking the stock with Buy rating on September 13, 2024, and set its price target to $40. On May 03, 2024, Wells Fargo initiated with a Overweight rating and assigned a price target of $34 on the stock. BofA Securities reiterated its Buy rating and increased its price target to $40 on June 29, 2020. BofA/Merrill initiated its recommendation with a Buy and recommended $25 as its price target on April 01, 2020. Barclays started tracking with a Overweight rating for this stock on March 11, 2019, and assigned it a price target of $26. In a note dated December 12, 2018, Wedbush reiterated an Outperform rating on this stock and boosted its target price from $31 to $33.
Kiniksa Pharmaceuticals International Plc experienced fluctuations in its stock price throughout the past year between $17.38 and $28.56. Currently, Wall Street analysts expect the stock to reach $36.33 within the next 12 months. Kiniksa Pharmaceuticals International Plc [NASDAQ: KNSA] shares were valued at $29.11 at the most recent close of the market. An investor can expect a potential return of 24.8% based on the average KNSA price forecast.
Analyzing the KNSA fundamentals
Trailing Twelve Months sales for Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] were 481.17M which represents 72.54% growth. Gross Profit Margin for this corporation currently stands at 0.81% with Operating Profit Margin at -0.03%, Pretax Profit Margin comes in at -0.01%, and Net Profit Margin reading is -0.04%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.04 and Total Capital is -0.03. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 27.97 points at the first support level, and at 26.83 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.98, and for the 2nd resistance point, it is at 30.85.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] is 3.66. Also, the Quick Ratio is 3.43, while the Cash Ratio stands at 1.62. Considering the valuation of this stock, the price to sales ratio is 4.41, the price to book ratio is 4.63.
Transactions by insiders
Recent insider trading involved Megna Michael R, Officer, that happened on Jun 03 ’25 when 15211.0 shares were purchased. Officer, Moat Ross completed a deal on Jun 03 ’25 to buy 27594.0 shares. Meanwhile, Officer Ragosa Mark bought 18299.0 shares on Jun 03 ’25.
